PIM use | Total n = 923 n (%) | Frailty score 0 n = 556 n (%) | Frailty score 1–2 n = 318 n (%) | Frailty score ≥ 3 n = 49 n (%) | p-valuea |
---|---|---|---|---|---|
Any PIM | 420 (45.5) | 208 (37.4) | 178 (56.0) | 34 (69.4) | < 0.001 |
PIMs | |||||
 NSAIDs | 71 (7.7) | 24 (4.3) | 38 (11.9) | 9 (18.4) | < 0.001 |
 Benzodiazepinesb | 90 (9.8) | 40 (7.2) | 40 (12.6) | 10 (20.4) | < 0.001 |
 Loop diuretics | 16 (1.7) | 3 (0.5) | 12 (3.8) | 1 (2.0) | 0.004 |
Antithrombotic drugs | |||||
 Antiplatelet drugs including aspirin | 84 (9.1) | 36 (6.5) | 44 (13.8) | 4 (8.2) | 0.007 |
 Combined therapy with multiple antithrombotic drugs | 21 (2.3) | 7 (1.3) | 13 (4.1) | 1 (2.0) | 0.04 |
 Muscarinic receptor antagonists | 26 (2.5) | 10 (1.8) | 12 (3.8) | 4 (8.2) | 0.006 |
 H2 receptor antagonists | 30 (3.3) | 12 (2.2) | 15 (4.7) | 3 (6.1) | 0.02 |
 Sulfonylureas | 39 (4.2) | 17 (3.1) | 18 (5.7) | 4 (8.2) | 0.021 |
 Thiazolidine derivatives | 11 (1.2) | 3 (0.5) | 7 (2.2) | 1 (2.0) | 0.039 |
 SSRIs | 12 (1.3) | 4 (0.7) | 6 (1.9) | 2 (4.1) | 0.025 |